DxS receives Biotechnology Award for Cancer product from BioNow
30-Nov-2006
According to the company, recent advances in the field of cancer drugs have provided DxS with an opportunity to develop the world's first tumour mutation analysis kit to identify patients who will respond well to certain lung cancer therapies. This new oncogene assay can detect the 29 most common somatic mutations in the Epidermal Growth Factor Receptor Gene, identifying mutations that are not visible by sequencing techniques.
Most read news
Organizations
DxS
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.